Clinical Efficacy Observation of Yiqi Huoxue Prescription in Treating Coronary Heart Disease with Qi Deficiency and Blood Stasis Syndrome After PCI

Not Applicable

Recruiting

• Conditions: Coronary heart disease

• Registration Number: ITMCTR2100004215
• Lead Sponsor: Affiliated Hospital of Chengdu University of traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Subjects meeting the diagnostic criteria of ACS;
2. Subjects aged 40 to 80 years;
3. Subjects with successful percutaneous coronary intervention (complete revascularization of target vessel);
4. Subjects with cardiac function I-III (NYHA classification);
5. Subjects who meet the syndrome differentiation standard of qi deficiency and blood stasis syndrome of chest stuffiness and heartache;
6. Subjects who signed informed consent and agreed to participate in the trial.

Exclusion Criteria

1. Patients who need continuous mechanical adjuvant therapy after successful interventional therapy;
2. Patients with severe liver, kidney, hematopoiesis, nervous system diseases, psychosis and malignant tumor;
3. Pregnant or lactating women;
4. Allergic constitution and patients with suspected or definite allergy to related drugs;
5. Patients with persistent atrial fibrillation and fatal arrhythmia;
6. Patients whose compliance is poor and the possibility of follow-up is poor;
7. Patients who are participating in other clinical trials or in recent 3 months.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
T-proBNP;